Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial

Fig. 2

a Kaplan–Meier analysis of OS and b subgroup analysis between erlotinib and GC groups in the intention-to-treat population and c the update Kaplan–Meier analysis of PFS. EGFR epidermal growth factor receptor, GC gemcitabine plus cisplatin, HR hazard ratio, OS overall survival, PFS progression-free survival

Back to article page